Arctic Bioscience – Invitation to presentation of Full Year 2021 results
Arctic Bioscience AS will publish its financial results for the full year 2021 on Thursday April 7, 2022, at 08:00 CEST.
The same day at 12:00 CEST, the company will host a webcast to present the results. Following the presentation, it will be opened for questions from the audience.
Webcast Details:
Arctic Bioscience AS FY 2021 webcast presentation:
Date: Thursday April 7, 2022
Time: 12.00 CEST
Format: Webcast and Q&A
Language: English
Link: https://streams.eventcdn.net/arcticbioscienceas/financial-results-fy-2021
Participants will be required to register to view the webcast and participate in the Q&A.
_________________________________________________________________________________________________________________
For more information, please contact
Christer Valderhaug
CEO Arctic Bioscience
Phone: +47 920 84 601
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing nutraceutical and pharmaceutical products based on unique bioactive marine compounds from herring roe.
The company is developing HRO350 – a novel investigational drug candidate based on herring roe. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Herring roe contains lipids that are essential in maintaining cell membranes and omega -3 fatty acids that contribute to the normal functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand. The strategy is to switch sales from bulk to finished goods and focus markets are USA and China.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.
This information is subject to the disclosure requirements in EU Market Abuse Regulations (MAR) 596/2014 article 19 number 3 and the Norwegian Securities Trading Act § 5-12.